about
Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitizationADAM metalloproteases and EGFR signallingExtreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancerUnderstanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models.TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independenceInsulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsQuantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targetsModulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancerConsensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.Overview of tyrosine kinase inhibitors in clinical breast cancer.Development of strategies for the use of anti-growth factor treatments.Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Evaluation of the current knowledge limitations in breast cancer research: a gap analysisGrowth factor receptor interplay and resistance in cancer.Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications.Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cellsSteroid hormone receptors and their clinical significance in cancer.Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
P50
Q24803435-E8374F43-3BB4-489A-94D4-88C2512588B9Q24803587-C94584E8-F8B3-4B30-9ACB-53A4EA279AACQ24806505-8A0AEE3D-550F-4B42-A663-B6B9FFCB35EBQ24813647-59EC5CED-E3CD-4A82-AA29-08DCDE897BACQ28201559-0368D8A5-37CF-4D28-8CCA-2C0ED14152E5Q28299546-30E76DEF-A07F-4AD7-B4DA-51A2731BFEA9Q28541545-1C399108-B7F9-42CC-8248-31CB6357DA9CQ34376333-0424CA4C-E9FA-4504-A01F-1D915228F0DCQ34435089-8FEC4C9A-8AA5-48FD-8358-3862829797BDQ34539617-221C51DA-A3CB-4C88-8208-08861530D7E6Q34857146-2CF7566E-6B3A-4F5F-B9B9-46CED8568CAEQ35558954-5D2E1D24-C038-4C49-8451-F28549297191Q36110138-50530900-ACF9-48A2-813B-ADD764F7D556Q36172210-353FA9A8-F5EB-4A96-9CBC-D29CFB6B7DF8Q36236568-19A1349E-098C-4E39-8D12-E8F07F21D514Q36236590-0EE498D2-B4B6-48A7-A577-26A34A65A9E8Q36236610-B3C30BD0-0D86-45E7-AF9B-89DD4A5B9E83Q36236624-E4CEB65C-12D5-49AB-A0CE-AE391323D822Q36236645-5B233820-ADFA-49C8-AD2D-4D1541567859Q36393289-BBE9CD43-32D5-4C8D-AFE0-7B1C316A7E8CQ36678664-8C4CD04E-3ED0-4B16-A769-A92BC9B21A1AQ36720694-7C41F4D3-97F5-4898-A951-1648B45CA530Q36720709-DB2C0498-A1A6-4171-85C7-595E57F72F97Q36720713-B86C2E51-3477-43CF-9FAD-FDF94808BCFCQ36814491-BABEDADB-6015-4D21-B93F-6C539B47D7E8Q36903310-F54DB158-012D-4102-9A50-5BF3C43736DDQ37131348-70DFC522-F7B2-48EC-B2B7-2D21909AAB0AQ37268503-9C1E66C5-4C1D-469F-A482-EAA0048C211AQ37385287-4DB115FD-D69B-4133-BA7D-75A56B6712E9Q37690245-65AE93A3-0B7A-416A-83AC-96785513BF19Q37929842-5C1B9136-F2E3-4D88-91B7-D60761FC3B79Q39352451-E096C1E8-DE5E-4EFF-9FA7-D614F2FCD7FEQ39872444-E62A5F17-BC8A-4300-B64B-4CF74C1C0B67Q39880360-17930B77-D220-479F-8B83-AC2A6601CCACQ39906003-FE1F0E90-563D-442E-A54E-0EBEBBE3574AQ40074875-F1A68C52-8295-4E8C-B877-D1D765835FF0Q40259343-76F462B9-52C6-4771-B519-3F5266D1D43DQ40342689-B9025015-F3E2-4D77-B9E5-C83AEB86B76AQ40355980-3B4B1356-D320-46AB-A8B0-C4329CA231E5Q40383001-938BF3A4-4AEB-4C24-AC7D-61372857E6AF
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Julia Gee
@ast
Julia Gee
@en
Julia Gee
@es
Julia Gee
@nl
Julia Gee
@sl
Юлия Чи
@ru
type
label
Julia Gee
@ast
Julia Gee
@en
Julia Gee
@es
Julia Gee
@nl
Julia Gee
@sl
Юлия Чи
@ru
prefLabel
Julia Gee
@ast
Julia Gee
@en
Julia Gee
@es
Julia Gee
@nl
Julia Gee
@sl
Юлия Чи
@ru
P1053
N-3995-2014
P106
P1153
7201491207
P21
P31
P3829
P496
0000-0001-6483-2015